Cardiovascular Risk Assessment in Diabetes Mellitus: Comparison of the General Framingham Risk Profile Versus the World Health Organization/International Society of Hypertension Risk Prediction Charts in Arabs—Clinical Implications
We estimated the prevalence of cardiovascular disease (CVD) risk and its clinical implications among 1 110 Omani patients with type 2 diabetes mellitus (DM) using 2 different CVD risk tools: the general Framingham risk profile (GFRP) and the joint World Health Organization/International Society of H...
Gespeichert in:
| Veröffentlicht in: | Angiology 2013-07, Vol.64 (5), p.336-342 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 342 |
|---|---|
| container_issue | 5 |
| container_start_page | 336 |
| container_title | Angiology |
| container_volume | 64 |
| creator | Al-Lawati, Jawad A. Barakat, Mohammed N. Al-Lawati, Najla A. Al-Maskari, Masoud Y. Elsayed, Medhat K. Mikhailidis, Dimitri P. Al-Zakwani, Ibrahim S. |
| description | We estimated the prevalence of cardiovascular disease (CVD) risk and its clinical implications among 1 110 Omani patients with type 2 diabetes mellitus (DM) using 2 different CVD risk tools: the general Framingham risk profile (GFRP) and the joint World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts. The GFRP tool identified higher proportion of patients compared with joint WHO/ISH tool at 10-year CVD risk 10% to |
| doi_str_mv | 10.1177/0003319712458349 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1356953860</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0003319712458349</sage_id><sourcerecordid>1356953860</sourcerecordid><originalsourceid>FETCH-LOGICAL-c205t-a41ed7782c03f17dba0c73a4576740bdfda8076d366d6d7322c0ebc91d892f5a3</originalsourceid><addsrcrecordid>eNp1kEtLAzEUhYMotlb3rmSWbkbzzmRZan1ARRBdD5kkI6nzqLkzgv_elFYXgqvL5XzncO9B6JzgK0KUusYYM0a0IpSLgnF9gKZEc5wTofghmm7lfKtP0AnAOq2CYHmMJpRqTgnVU8QWJrrQfxqwY2Ni9hzgPZsDeIDWd0MWuuwmmMoPHrJH3zRhGOEUHdWmAX-2nzP0ert8Wdznq6e7h8V8lVuKxZAbTrxTqqAWs5ooVxlsFTNcKKk4rlztTIGVdExKJ51iNIG-spq4QtNaGDZDl7vcTew_Rg9D2Qaw6QjT-X6EkjAhtWCFxAnFO9TGHiD6utzE0Jr4VRJcbqsq_1aVLBf79LFqvfs1_HSTgHwHgHnz5bofY5e-_T_wG-ecb0I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1356953860</pqid></control><display><type>article</type><title>Cardiovascular Risk Assessment in Diabetes Mellitus: Comparison of the General Framingham Risk Profile Versus the World Health Organization/International Society of Hypertension Risk Prediction Charts in Arabs—Clinical Implications</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Al-Lawati, Jawad A. ; Barakat, Mohammed N. ; Al-Lawati, Najla A. ; Al-Maskari, Masoud Y. ; Elsayed, Medhat K. ; Mikhailidis, Dimitri P. ; Al-Zakwani, Ibrahim S.</creator><creatorcontrib>Al-Lawati, Jawad A. ; Barakat, Mohammed N. ; Al-Lawati, Najla A. ; Al-Maskari, Masoud Y. ; Elsayed, Medhat K. ; Mikhailidis, Dimitri P. ; Al-Zakwani, Ibrahim S.</creatorcontrib><description>We estimated the prevalence of cardiovascular disease (CVD) risk and its clinical implications among 1 110 Omani patients with type 2 diabetes mellitus (DM) using 2 different CVD risk tools: the general Framingham risk profile (GFRP) and the joint World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts. The GFRP tool identified higher proportion of patients compared with joint WHO/ISH tool at 10-year CVD risk 10% to <20% and at 20% to <30%. At CVD risk ≥30%, both assessment tools identified similar proportions of patients (22% vs 24%; P=.120). Compared with WHO/ISH charts, the GFRP identified almost double the number of men eligible for aspirin treatment at CVD risk thresholds of ≥10% (86% vs 43%). In women, the proportions were, 66% and 45%, respectively. For statins, the figures were, 60% and 37%, for men and 28% and 36%, for women. In conclusion, the GFRP overestimates the number of patients eligible for primary prevention of CVD compared with the joint WHO/ISH method.</description><identifier>ISSN: 0003-3197</identifier><identifier>EISSN: 1940-1574</identifier><identifier>DOI: 10.1177/0003319712458349</identifier><identifier>PMID: 22942129</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Arabs - statistics & numerical data ; Cardiovascular Agents - economics ; Cardiovascular Agents - therapeutic use ; Cardiovascular Diseases - diagnosis ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - therapy ; Cohort Studies ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - ethnology ; Drug Costs ; Female ; Health Status Indicators ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Male ; Middle Aged ; Oman - epidemiology ; Practice Patterns, Physicians ; Prevalence ; Risk Factors</subject><ispartof>Angiology, 2013-07, Vol.64 (5), p.336-342</ispartof><rights>The Author(s) 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c205t-a41ed7782c03f17dba0c73a4576740bdfda8076d366d6d7322c0ebc91d892f5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0003319712458349$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0003319712458349$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,21800,27905,27906,43602,43603</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22942129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Al-Lawati, Jawad A.</creatorcontrib><creatorcontrib>Barakat, Mohammed N.</creatorcontrib><creatorcontrib>Al-Lawati, Najla A.</creatorcontrib><creatorcontrib>Al-Maskari, Masoud Y.</creatorcontrib><creatorcontrib>Elsayed, Medhat K.</creatorcontrib><creatorcontrib>Mikhailidis, Dimitri P.</creatorcontrib><creatorcontrib>Al-Zakwani, Ibrahim S.</creatorcontrib><title>Cardiovascular Risk Assessment in Diabetes Mellitus: Comparison of the General Framingham Risk Profile Versus the World Health Organization/International Society of Hypertension Risk Prediction Charts in Arabs—Clinical Implications</title><title>Angiology</title><addtitle>Angiology</addtitle><description>We estimated the prevalence of cardiovascular disease (CVD) risk and its clinical implications among 1 110 Omani patients with type 2 diabetes mellitus (DM) using 2 different CVD risk tools: the general Framingham risk profile (GFRP) and the joint World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts. The GFRP tool identified higher proportion of patients compared with joint WHO/ISH tool at 10-year CVD risk 10% to <20% and at 20% to <30%. At CVD risk ≥30%, both assessment tools identified similar proportions of patients (22% vs 24%; P=.120). Compared with WHO/ISH charts, the GFRP identified almost double the number of men eligible for aspirin treatment at CVD risk thresholds of ≥10% (86% vs 43%). In women, the proportions were, 66% and 45%, respectively. For statins, the figures were, 60% and 37%, for men and 28% and 36%, for women. In conclusion, the GFRP overestimates the number of patients eligible for primary prevention of CVD compared with the joint WHO/ISH method.</description><subject>Adult</subject><subject>Aged</subject><subject>Arabs - statistics & numerical data</subject><subject>Cardiovascular Agents - economics</subject><subject>Cardiovascular Agents - therapeutic use</subject><subject>Cardiovascular Diseases - diagnosis</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - therapy</subject><subject>Cohort Studies</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - ethnology</subject><subject>Drug Costs</subject><subject>Female</subject><subject>Health Status Indicators</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oman - epidemiology</subject><subject>Practice Patterns, Physicians</subject><subject>Prevalence</subject><subject>Risk Factors</subject><issn>0003-3197</issn><issn>1940-1574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEtLAzEUhYMotlb3rmSWbkbzzmRZan1ARRBdD5kkI6nzqLkzgv_elFYXgqvL5XzncO9B6JzgK0KUusYYM0a0IpSLgnF9gKZEc5wTofghmm7lfKtP0AnAOq2CYHmMJpRqTgnVU8QWJrrQfxqwY2Ni9hzgPZsDeIDWd0MWuuwmmMoPHrJH3zRhGOEUHdWmAX-2nzP0ert8Wdznq6e7h8V8lVuKxZAbTrxTqqAWs5ooVxlsFTNcKKk4rlztTIGVdExKJ51iNIG-spq4QtNaGDZDl7vcTew_Rg9D2Qaw6QjT-X6EkjAhtWCFxAnFO9TGHiD6utzE0Jr4VRJcbqsq_1aVLBf79LFqvfs1_HSTgHwHgHnz5bofY5e-_T_wG-ecb0I</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Al-Lawati, Jawad A.</creator><creator>Barakat, Mohammed N.</creator><creator>Al-Lawati, Najla A.</creator><creator>Al-Maskari, Masoud Y.</creator><creator>Elsayed, Medhat K.</creator><creator>Mikhailidis, Dimitri P.</creator><creator>Al-Zakwani, Ibrahim S.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201307</creationdate><title>Cardiovascular Risk Assessment in Diabetes Mellitus</title><author>Al-Lawati, Jawad A. ; Barakat, Mohammed N. ; Al-Lawati, Najla A. ; Al-Maskari, Masoud Y. ; Elsayed, Medhat K. ; Mikhailidis, Dimitri P. ; Al-Zakwani, Ibrahim S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c205t-a41ed7782c03f17dba0c73a4576740bdfda8076d366d6d7322c0ebc91d892f5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Arabs - statistics & numerical data</topic><topic>Cardiovascular Agents - economics</topic><topic>Cardiovascular Agents - therapeutic use</topic><topic>Cardiovascular Diseases - diagnosis</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - therapy</topic><topic>Cohort Studies</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - ethnology</topic><topic>Drug Costs</topic><topic>Female</topic><topic>Health Status Indicators</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oman - epidemiology</topic><topic>Practice Patterns, Physicians</topic><topic>Prevalence</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Al-Lawati, Jawad A.</creatorcontrib><creatorcontrib>Barakat, Mohammed N.</creatorcontrib><creatorcontrib>Al-Lawati, Najla A.</creatorcontrib><creatorcontrib>Al-Maskari, Masoud Y.</creatorcontrib><creatorcontrib>Elsayed, Medhat K.</creatorcontrib><creatorcontrib>Mikhailidis, Dimitri P.</creatorcontrib><creatorcontrib>Al-Zakwani, Ibrahim S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Angiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Al-Lawati, Jawad A.</au><au>Barakat, Mohammed N.</au><au>Al-Lawati, Najla A.</au><au>Al-Maskari, Masoud Y.</au><au>Elsayed, Medhat K.</au><au>Mikhailidis, Dimitri P.</au><au>Al-Zakwani, Ibrahim S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiovascular Risk Assessment in Diabetes Mellitus: Comparison of the General Framingham Risk Profile Versus the World Health Organization/International Society of Hypertension Risk Prediction Charts in Arabs—Clinical Implications</atitle><jtitle>Angiology</jtitle><addtitle>Angiology</addtitle><date>2013-07</date><risdate>2013</risdate><volume>64</volume><issue>5</issue><spage>336</spage><epage>342</epage><pages>336-342</pages><issn>0003-3197</issn><eissn>1940-1574</eissn><abstract>We estimated the prevalence of cardiovascular disease (CVD) risk and its clinical implications among 1 110 Omani patients with type 2 diabetes mellitus (DM) using 2 different CVD risk tools: the general Framingham risk profile (GFRP) and the joint World Health Organization/International Society of Hypertension (WHO/ISH) risk prediction charts. The GFRP tool identified higher proportion of patients compared with joint WHO/ISH tool at 10-year CVD risk 10% to <20% and at 20% to <30%. At CVD risk ≥30%, both assessment tools identified similar proportions of patients (22% vs 24%; P=.120). Compared with WHO/ISH charts, the GFRP identified almost double the number of men eligible for aspirin treatment at CVD risk thresholds of ≥10% (86% vs 43%). In women, the proportions were, 66% and 45%, respectively. For statins, the figures were, 60% and 37%, for men and 28% and 36%, for women. In conclusion, the GFRP overestimates the number of patients eligible for primary prevention of CVD compared with the joint WHO/ISH method.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>22942129</pmid><doi>10.1177/0003319712458349</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-3197 |
| ispartof | Angiology, 2013-07, Vol.64 (5), p.336-342 |
| issn | 0003-3197 1940-1574 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1356953860 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Aged Arabs - statistics & numerical data Cardiovascular Agents - economics Cardiovascular Agents - therapeutic use Cardiovascular Diseases - diagnosis Cardiovascular Diseases - epidemiology Cardiovascular Diseases - therapy Cohort Studies Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - ethnology Drug Costs Female Health Status Indicators Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - economics Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Male Middle Aged Oman - epidemiology Practice Patterns, Physicians Prevalence Risk Factors |
| title | Cardiovascular Risk Assessment in Diabetes Mellitus: Comparison of the General Framingham Risk Profile Versus the World Health Organization/International Society of Hypertension Risk Prediction Charts in Arabs—Clinical Implications |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A19%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiovascular%20Risk%20Assessment%20in%20Diabetes%20Mellitus:%20Comparison%20of%20the%20General%20Framingham%20Risk%20Profile%20Versus%20the%20World%20Health%20Organization/International%20Society%20of%20Hypertension%20Risk%20Prediction%20Charts%20in%20Arabs%E2%80%94Clinical%20Implications&rft.jtitle=Angiology&rft.au=Al-Lawati,%20Jawad%20A.&rft.date=2013-07&rft.volume=64&rft.issue=5&rft.spage=336&rft.epage=342&rft.pages=336-342&rft.issn=0003-3197&rft.eissn=1940-1574&rft_id=info:doi/10.1177/0003319712458349&rft_dat=%3Cproquest_cross%3E1356953860%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1356953860&rft_id=info:pmid/22942129&rft_sage_id=10.1177_0003319712458349&rfr_iscdi=true |